Maryland: Insurers Can’t Bill Patients for Monoclonal Antibodies
Maryland Insurance Commissioner Kathleen Birrane says if patients receive monoclonal antibody treatments for COVID-19, they can’t be billed for the therapy if their health insurance carrier operates in the state. Birrane says she invoked emergency powers to require Maryland health insurers to cover Bamlanivimab, Casirivimab, and Imdevimab, all used to treat COVID-19. Birrane instructed insurers, “You have to cover this, you can’t claim that it’s experimental, and when you cover it, there can be no cost sharing.” As a result, 100 percent of the cost of administration has to be covered by the insurer. Birrane said she wanted to make sure that the costs of administering the therapy wouldn’t result in people not being able to get the treatment.